Operator: Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue Expanded gross margins to 48% in continuing operations and delivered 52% year-over-year.
GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 10,752 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $4.16, for a total transaction of $44,728.32. Following the completion of the sale, the chief executive officer now owns 42,689 shares […]
Altium Capital Management LP acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,588,000 shares of the company’s stock, valued at approximately $1,675,000. Altium Capital Management LP owned 18.97% of GeneDx at the […]